Moffitt Cancer Center launches $600M radiopharmaceutical and theranostics program

Moffitt Cancer Center is launching a radiopharmaceutical program with a $600 million investment, building radiochemistry labs and an Integrated Theranostics Center to accelerate cancer theranostics research and clinical translation.

• The Moffitt Radiopharmaceutical Program at the 775-acre Speros campus includes new radiochemistry labs in the 255,000-square-foot Discovery and Innovation Center opening this fall.
• The planned Integrated Theranostics Center will house dedicated radioisotope production and translational research; program co-leads are Ghassan El-Haddad, MD, and Josh Carpenter, DPhil.
• The initiative is part of the FORGE coalition with the University of South Florida and other partners, projected to generate $2.6 billion in economic impact and over 11,000 jobs.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.